Articles from Alumis Inc.

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that company management will participate in the following investor conferences in September:

– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis –

– Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory submission –

Alumis Inc., a precision immunology company that is reimagining the discovery, development and treatment of autoimmune disorders, today announced that the first patient has been dosed in Stride, a Phase 2 clinical trial of ESK-001 for the treatment of patients with moderate to severe plaque psoriasis. ESK-001 is a highly selective and potentially best in class allosteric tyrosine kinase 2 (TYK2) inhibitor.

Alumis Inc., a precision immunology company that is reimagining the discovery, development and treatment of autoimmune disorders, today announced that Jörn Drappa, M.D., Ph.D., has been appointed as chief medical officer. Dr. Drappa brings more than 30 years of healthcare and pharmaceutical industry experience, having led the advancement of dozens of early to late-stage drug development programs for autoimmune disorders. In addition, Roman G. Rubio, M.D., has been appointed as senior vice president, clinical development and translational medicine, bringing a successful track record of overseeing numerous early and later-stage clinical development programs.